Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours. 2013

Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

The feasibility of cancer immunotherapy mediated by T lymphocytes is now a clinical reality. Indeed, many tumour associated antigens have been identified for cytotoxic CD8 T cells, which are believed to be key mediators of tumour rejection. However, for aggressive malignancies in specialised anatomic sites such as the brain, a limiting factor is suboptimal tumour infiltration by CD8 T cells. Here we take advantage of recent advances in T cell biology to differentially polarise CD4 T cells in order to explore their capacity to enhance immunotherapy. We used an adoptive cell therapy approach to work with clonal T cell populations of defined specificity. Th1 CD4 T cells preferentially homed to and accumulated within intracranial tumours compared with Th2 CD4 T cells. Moreover, tumour-antigen specific Th1 CD4 T cells enhanced CD8 T cell recruitment and function within the brain tumour bed. Survival of mice bearing intracranial tumours was significantly prolonged when CD4 and CD8 T cells were co-transferred. These results should encourage further definition of tumour antigens recognised by CD4 T cells, and exploitation of both CD4 and CD8 T cell subsets to optimise T cell therapy of cancer.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016201 Receptors, Lymphocyte Homing Cell surface glycoproteins on lymphocytes and other leukocytes that mediate adhesion to specialized blood vessels called high endothelial venules. Several different classes of lymphocyte homing receptors have been identified, and they appear to target different surface molecules (addressins) on high endothelial venules in different tissues. The adhesion plays a crucial role in the trafficking of lymphocytes. Hermes Antigen Family,Homing Receptors, T-Cell,Lymphocyte Homing Receptors,Homing Receptor, Lymph Node,Lymph Node Homing Receptor,Receptor, Lymph Node Homing,Antigen Family, Hermes,Homing Receptors, Lymphocyte,Homing Receptors, T Cell,Receptors, T-Cell Homing,T-Cell Homing Receptors
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell
D016764 Cell Polarity Orientation of intracellular structures especially with respect to the apical and basolateral domains of the plasma membrane. Polarized cells must direct proteins from the Golgi apparatus to the appropriate domain since tight junctions prevent proteins from diffusing between the two domains. Cell Polarities,Polarities, Cell,Polarity, Cell

Related Publications

Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
May 1998, Journal of neuroimmunology,
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
May 2011, Journal of immunotherapy (Hagerstown, Md. : 1997),
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
August 2002, The Journal of laryngology and otology,
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
November 2004, Journal of translational medicine,
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
May 2007, Infection and immunity,
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
March 1997, Science (New York, N.Y.),
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
August 1998, Journal of immunology (Baltimore, Md. : 1950),
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
January 1998, Vaccine,
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
April 2009, Current opinion in immunology,
Sabine Hoepner, and Jacelyn M S Loh, and Cristina Riccadonna, and Madiha Derouazi, and Céline Yacoub Maroun, and Pierre-Yves Dietrich, and Paul R Walker
March 1995, Immunity,
Copied contents to your clipboard!